Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-25-015016
Filing Date
2025-02-06
Accepted
2025-02-06 08:00:04
Documents
2
Period of Report
2025-02-04

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1579
2 EX-24 mcrb-ex24.htm EX-24 13754
  Complete submission text file 0000950170-25-015016.txt   16843
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Issuer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O SERES THERAPEUTICS, INC. 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address
Woerle Hans-Juergen (Reporting) CIK: 0002046489 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37465 | Film No.: 25595503